<DOC>
	<DOC>NCT02167945</DOC>
	<brief_summary>The purpose of this study is to evaluate Long-term Outcomes following treatment with ABT-450/r/ABT-267, ABT-333 with or without RBV in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection</brief_summary>
	<brief_title>A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>1. Females must be postmenopausal for more than 2 years or surgically sterile or practicing specific forms of birth control 2. Chronic hepatitis C, genotype 1infection (HCV RNA level greater than 1,000 IU/mL at screening) 3. HCV genotype 1 infection per screening laboratory result 1. Use of contraindicated medications within 2 weeks of dosing 2. Abnormal laboratory tests 3. Positive hepatitis B surface antigen and antiHuman Immunodeficiency Virus Antibody 4. Clinical history of liver decompensation 5. Presence of hepatocellular carcinoma at screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Na√Øve</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Non responder</keyword>
	<keyword>Relapser</keyword>
	<keyword>Null responder</keyword>
	<keyword>Treatment-Experienced</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Hepatitis C Genotype 1</keyword>
	<keyword>Compensated Cirrhosis</keyword>
	<keyword>Hepatitis C Virus</keyword>
</DOC>